Amicus Therapeutics (NASDAQ:FOLD) Given “Hold” Rating at Needham & Company LLC

Amicus Therapeutics (NASDAQ:FOLD)‘s stock had its “hold” rating reiterated by analysts at Needham & Company LLC in a research note issued on Friday, Benzinga reports.

Other equities research analysts also recently issued reports about the company. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $22.00 price target on shares of Amicus Therapeutics in a research report on Thursday, February 29th. Bank of America lowered their target price on Amicus Therapeutics from $14.00 to $13.00 and set a “buy” rating on the stock in a report on Friday. Finally, JPMorgan Chase & Co. cut their price target on Amicus Therapeutics from $21.00 to $19.00 and set an “overweight” rating for the company in a report on Monday, March 18th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Amicus Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $18.50.

Amicus Therapeutics Trading Down 6.5 %

Shares of NASDAQ:FOLD opened at $9.48 on Friday. Amicus Therapeutics has a 1 year low of $9.24 and a 1 year high of $14.57. The company has a current ratio of 2.88, a quick ratio of 2.52 and a debt-to-equity ratio of 2.42. The firm has a fifty day moving average price of $11.29 and a 200 day moving average price of $11.96. The stock has a market capitalization of $2.81 billion, a PE ratio of -18.59 and a beta of 0.80.

Amicus Therapeutics (NASDAQ:FOLD) last issued its quarterly earnings data on Wednesday, February 28th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.05). Amicus Therapeutics had a negative return on equity of 119.46% and a negative net margin of 37.96%. The firm had revenue of $115.08 million during the quarter, compared to analyst estimates of $115.11 million. Analysts expect that Amicus Therapeutics will post 0.01 EPS for the current fiscal year.

Insider Buying and Selling at Amicus Therapeutics

In related news, CEO Bradley L. Campbell sold 7,500 shares of the firm’s stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $10.07, for a total value of $75,525.00. Following the completion of the transaction, the chief executive officer now directly owns 886,654 shares of the company’s stock, valued at $8,928,605.78. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Amicus Therapeutics news, Chairman John F. Crowley sold 31,614 shares of Amicus Therapeutics stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $13.81, for a total transaction of $436,589.34. Following the sale, the chairman now directly owns 697,628 shares of the company’s stock, valued at $9,634,242.68. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Bradley L. Campbell sold 7,500 shares of the company’s stock in a transaction that occurred on Wednesday, May 1st. The shares were sold at an average price of $10.07, for a total value of $75,525.00. Following the completion of the sale, the chief executive officer now owns 886,654 shares in the company, valued at $8,928,605.78. The disclosure for this sale can be found here. Insiders sold a total of 55,208 shares of company stock valued at $732,930 in the last quarter. Corporate insiders own 2.20% of the company’s stock.

Institutional Trading of Amicus Therapeutics

Several institutional investors have recently bought and sold shares of the stock. Van ECK Associates Corp lifted its holdings in shares of Amicus Therapeutics by 23.1% during the fourth quarter. Van ECK Associates Corp now owns 4,657 shares of the biopharmaceutical company’s stock valued at $66,000 after acquiring an additional 873 shares during the period. China Universal Asset Management Co. Ltd. increased its position in shares of Amicus Therapeutics by 97.5% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,368 shares of the biopharmaceutical company’s stock worth $90,000 after purchasing an additional 3,638 shares in the last quarter. Park Avenue Securities LLC acquired a new stake in shares of Amicus Therapeutics during the 3rd quarter worth about $128,000. Campbell & CO Investment Adviser LLC bought a new position in Amicus Therapeutics during the 3rd quarter valued at about $134,000. Finally, Calton & Associates Inc. acquired a new position in Amicus Therapeutics in the fourth quarter valued at about $142,000.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.